Every letter we have printed

The version I would accept is a mark that renders the determination date, the molecule and the report number in the image, links to the report and greys itself after twelve months. Everything in that list is trivial to build and none of it exists.

The endpoints chosen are almost entirely anthropometric, and the endpoints readers care about are frequently not. That mismatch is a funding and feasibility question rather than a scientific one, and it should be described as such.

Dropout after withdrawal is differential by definition: people in the withdrawal arm have less reason to attend. Any analysis that does not address that is measuring attendance as much as outcome.

Trial participants know they may be withdrawn, and expectation affects behaviour in any unblinded or partially blinded design. Nobody in this literature has measured what participants believed had happened to them.

Gallbladder motility gets a sentence in most reviews and deserves more, since it is a distinct mechanism with a distinct time course and it accounts for a category of reported events that the emptying story does not explain.

A point about the exposure profile rather than the receptor. Peak-to-trough variation differs substantially between compounds in this class, and a mechanism driven by peak exposure will present differently from one driven by average exposure. The literature rarely separates the two.

Case reports are hypothesis-generating and are cited as though they were confirmatory. A single well-documented case is genuinely valuable and it establishes that something can happen, not how often.

Seasonal variation makes a single documented shipment close to meaningless. A supplier’s packing that performs well in March may not in July, and any claim about cold-chain performance should be dated.

Ask which indicator and at what threshold. There are several products with very different trigger conditions and the carton usually says only that one is present.

Point-of-care gastric ultrasound is the assessment that actually answers the question, and availability rather than evidence is the limiting factor. Where it exists it replaces a rule of thumb with a look.

The guidance documents themselves are freely available and rarely read by the people arguing about them. Linking the primary sources, as your reference desk does, is worth more than another summary of them.

A note about what people actually do, from somebody who reads a great deal of it. The most common response reported is to wait, and waiting is almost never described in the formal literature as a strategy even though it appears to be the dominant one.

Baseline transit varies enormously across a healthy population and is almost never measured before the intervention. A study without baseline measurement is estimating a change from an assumed starting point.

Your account treats the effect as uniform along the tract. The receptor distribution is not uniform, and the upper and lower symptoms in the reported data behave differently over time, which is consistent with more than one mechanism operating.

Estimated glomerular filtration rate is calculated from creatinine, so everything that moves creatinine moves the estimate. During substantial change in body composition the equation is being applied outside the conditions in which it was derived, and the estimate carries more uncertainty than the single number suggests.

Lipase and amylase are poor screening tests in an asymptomatic person, and elevations without symptoms are common and usually of no consequence. Ordering them routinely generates a great deal of anxiety and very little information.

A small thing but it matters in practice: your table gives amylase and lipase rising as a finding of unclear significance. In my laboratory we no longer report amylase at all for suspected pancreatitis, because lipase is more sensitive and more specific and having both invites the wrong one to be acted on.

Every certificate I hold has a header with a company name and no company address. It is a small thing until you need to write to somebody, at which point the document has told you who did the work and given you no means of reaching them.

A note on page numbering. Certificates that are not marked page one of two are trivially separable, and the second page is where the method usually lives. I have twice received a first page alone and had no way to know a second existed.

A technical query on your identity row: you specify 4111.1 Da monoisotopic with a tolerance of ±10 ppm, which is 0.04 daltons. Is that not tighter than most contract laboratories will commit to on a peptide of that size?

Corrections are the missing practice. Every publication has a mechanism for saying it got something wrong; almost no testing arrangement in this trade does. A reissued certificate with a note explaining what changed would be an ordinary professional courtesy and I have seen it twice.

Water content by Karl Fischer is inexpensive, fast and almost never reported. For a lyophilised powder it bears directly on stability, and it is the determination I would add first if I could add only one. Material described as being for research use only is not approved for human use in any case, so the argument for measuring it is a scientific one rather than a safety one.

Anybody can typeset a certificate. The useful check is not the appearance of the document but whether the issuing laboratory will confirm the report number, and in my experience the laboratories will, quickly and without fuss, if you write to them directly.

I would like the retention policy printed on the certificate. A laboratory that keeps raw data for seven years and one that discards it after ninety days offer very different documents, and the difference only becomes visible at the moment you need to go back to it.

I have a certificate with an expiry date twenty-four months from manufacture and no stability data behind it, which your article says is a claim the documentation cannot support. The supplier tells me it is industry standard. Is it?

We started photographing the vial, the label and the seal before sending anything for testing, and it has settled two disputes since. It costs a minute and it converts a claim about provenance into a record of it.

The house style of giving the size of the evidence base before the finding has changed how I read everything else. It is a small habit with a large effect.

Compensatory adaptation over weeks is the systematic limit on any acute mechanistic account, and it is not measurable in the assays that generate the mechanistic claims.

Receptor pharmacology tells you what can happen and outcome studies tell you what does. Presenting the first as though it settled the second is the commonest error in coverage of this class, and it is committed by people who know better.

I found the section on the area postrema genuinely clarifying. I had assumed nausea was a stomach problem and had been treating it as one, unsuccessfully, for four months.

The activity ratio is a design parameter chosen by the chemists, and different programmes chose differently for reasons that are published. Reading those design rationales is more informative than any comparison of outcomes.

The published pharmacokinetic parameters are derived from the approved formulations, and nothing establishes that material of unknown formulation behaves the same way. Excipients and concentration both affect absorption for compounds of this kind.

The distinction that matters is not blind against named but who chose the sample. A blind submission of a vial the seller selected is not blind in any sense that protects the reader, and the word is doing all the work in that sentence.

Anonymity for the purchaser and anonymity for the supplier are different protections and they are frequently confused. The first keeps the sample honest; the second is a courtesy that mostly benefits the party being tested.

I submitted a vial to one of these services last year, got a result three points below what the vendor advertised, and did not know what to do with it. Your article explains why: I had one measurement on one vial, no method comparison, and no way to know if my vial was representative. I still do not know what to do with it, but I understand the shape of not knowing.

I administer a small purchasing budget and I have stopped treating marks of this kind as evidence at all. Not because they are dishonest, but because I cannot tell from the mark which of the honest cases I am looking at, and a signal I cannot decode is not a signal.

Ambient during transport home from a delivery point is part of the in-use history and is never counted. A parcel collected on a warm afternoon and carried across town has had an excursion before anybody opened it.

Aggregation during storage is invisible to inspection and to most of what people commission afterwards. A clear solution is not evidence of an intact one, and this is the failure mode that the visual check cannot catch.

I run a small analytical laboratory and I want to defend the twelve-minute method. It is fit for the purpose it is sold for: confirming that a sample is broadly what it claims to be, at a price a private buyer will actually pay. The problem is not the method. It is suppliers printing its output as though it were a release specification.

Why anonymise the four services? Naming them is the only way a reader can act on this.